Skip to content

Zepbound vs Mounjaro: what is the difference?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Zepbound vs Mounjaro is two brands of tirzepatide, each with its own FDA label. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight reduction and obstructive sleep apnea. LillyDirect self-pay is $499 a month for Mounjaro at every strength, and $299 to $449 for Zepbound vials or KwikPen refilled on time.

Source: LillyDirect self-pay

Key takeaways

  • Both contain tirzepatide from Eli Lilly, but each has its own label, approved uses and prices.
  • Mounjaro's uses are in type 2 diabetes. Zepbound's are weight reduction and sleep apnea in adults with obesity.
  • Paying cash? LillyDirect's Mounjaro pen is $499 a month. Zepbound vials or KwikPen top out at $449 with on-time refills.
  • The two aren't taken together. The Zepbound label says use with other tirzepatide products isn't recommended.
  • The strengths match, but no label says your Mounjaro strength carries over. Your prescriber decides where you start.

Mounjaro vs Zepbound, side by side

From each FDA label and our verified price records
MounjaroZepbound
Active ingredienttirzepatidetirzepatide
MakerEli Lilly and CompanyEli Lilly and Company
FDA-approved uses
  • adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events
  • reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition
  • moderate to severe obstructive sleep apnea (OSA) in adults with obesity
How it is takenweekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial)weekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial)
Strengths2.5 to 15 mg2.5 to 15 mg
Label starting dose
  • 2.5 mg weekly
  • 2.5 mg weekly
Cheapest verified self-pay$499 per fill at 15 mg
LillyDirect self-pay
$449 per fill at 15 mg
LillyDirect self-pay
With covering commercial insurance$25 with the manufacturer card$25 with the manufacturer card
Medicare GLP-1 BridgeNoYes: KwikPen (multi-dose, 4 weekly doses)
LabelRevised: 8/2026 (DailyMed version 40)Revised: 8/2026 (DailyMed version 40)
Mounjaro: most common reactions on the label · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
Reaction15 mgPlacebo
Nausea18%4%
Diarrhea17%9%
Decreased Appetite11%1%
Vomiting9%2%
Constipation7%1%
Dyspepsia5%3%
Zepbound: most common reactions on the label · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
Reaction15 mgPlacebo
Nausea28%8%
Diarrhea23%8%
Vomiting13%2%
Constipation11%5%
Abdominal Pain10%5%
Dyspepsia10%4%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Mounjaro and Zepbound come from the same company, contain the same molecule (tirzepatide) and are sold in the same six strengths. If you only looked at the dose ladder, you couldn’t tell them apart. The differences are in what each label approves, how each is priced and which programs will pay for it. Those differences decide which one you’re prescribed.

Which one suits whom?

  • You have type 2 diabetes. Mounjaro is the brand labeled for it, including in children 10 and older, and for reducing cardiovascular risk in adults with type 2 diabetes who are at high risk.
  • You’re being treated for weight. Zepbound is approved to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition.
  • You have moderate to severe obstructive sleep apnea and obesity. That use is on the Zepbound label only.
  • You’re paying cash. Zepbound’s self-pay vial and KwikPen cost less than Mounjaro’s self-pay pen at every strength, as long as you refill on time.
  • You’re on Medicare. Mounjaro for diabetes runs through Part D. Zepbound has a Part D route for sleep apnea and a Bridge route, KwikPen only, for weight management.

Your diagnosis picks the brand. Your prescriber writes for the one whose label fits. If you have type 2 diabetes and also want treatment for weight, ask how the two labels apply to you before you look at price.

What is each one approved for?

Mounjaro’s label has two uses, both in type 2 diabetes: improving blood sugar control, alongside diet and exercise, in adults and children 10 years of age and older, and reducing the risk of major adverse cardiovascular events (serious heart and blood vessel events) in adults with type 2 diabetes at high risk for them.

Zepbound’s label also has two, neither of them diabetes: long-term weight reduction in adults with obesity or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity. The label says Zepbound is used with a reduced-calorie diet and increased physical activity, and that its safety and effectiveness have not been established in children.

The Zepbound label adds a limit that matters here: coadministration with other tirzepatide-containing products is not recommended. The two brands are never stacked.

How do the doses and forms compare?

On dosing, the labels are close, but they aren’t word for word alike.

Both start at 2.5 mg once weekly, both move in 2.5 mg steps after at least 4 weeks on the current dose, and both top out at 15 mg in adults. Both are injected under the skin of the abdomen or thigh, or by another person in the back of the upper arm, at any time of day, with or without meals.

The differences:

  • Why the dose goes up. The Mounjaro label says to increase “if additional glycemic control is needed.” The Zepbound label names maintenance dosages (the doses you stay on): 5 mg, 10 mg or 15 mg for weight reduction, and 10 mg or 15 mg for sleep apnea. On Zepbound, 2.5 mg is for starting treatment and isn’t approved as a maintenance dosage.
  • Children. Mounjaro’s maximum is 10 mg once weekly in children. Zepbound has no use in children.
  • Forms. Both labels list a single-dose pen, a single-dose vial, a multi-dose vial and a KwikPen. Both tell prescribers to make sure you’re trained on the form you get, and again if it changes.

The form matters mostly for price, as the next section shows. The pen vs vial vs pill comparer works out cost per fill for each, and the dosing guide has the full ladders.

What does each one cost?

Here the two brands are far apart, even though the molecule and strengths match:

Mounjaro. Every price we hold is for the single-dose pen. LillyDirect self-pay starts at $499 a month, the same at every strength, with no refill-window rule. The list price (the full price before any discount) is $1,112.16 per fill. With commercial insurance that covers Mounjaro, the savings card lowers a fill to as little as $25. If the plan doesn’t cover it, the card price is $499.

Zepbound. Self-pay pricing is by strength and applies to the single-dose vial and the KwikPen: $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg. For those higher strengths, you keep the price only if you refill within 45 days of getting the last fill. Miss that and 10 mg and above cost $699. The single-dose pen has no self-pay program price and lists at $1,086.37 per fill. With covered commercial insurance, the savings card brings the pen to as little as $25.

A year at 15 mg comes to $6,487 for Mounjaro and $5,837 for Zepbound vials refilled on time. Vials need syringes and needles, and the KwikPen needs pen needles, bought separately.

The self-pay gap doesn’t mean you can choose the cheaper brand. The prescription has to match your diagnosis. The Mounjaro cost and Zepbound cost pages rank every route, the 45-day rule page explains the refill window, and the cost calculator totals either drug over a year.

How do insurance and Medicare treat them?

Insurers handle Mounjaro and Zepbound as two different drugs.

Commercial plans. A plan may cover Mounjaro for type 2 diabetes, often with prior authorization (the plan’s approval before it pays) or proof of diagnosis, and exclude Zepbound for weight management, or apply separate rules to each. Ask about the exact brand and your diagnosis when you call the number on your insurance card. The prior authorization guide explains what plans ask for.

Medicare. CMS lists type 2 diabetes as an indication eligible for Part D coverage, so Mounjaro goes through your Part D plan. For Zepbound, CMS names moderate to severe obstructive sleep apnea in adults with obesity as a use coverable under Part D. For weight management, the Medicare GLP-1 Bridge covers the Zepbound KwikPen at a $50 copay. Single-dose pens and vials aren’t included, and people with type 2 diabetes aren’t eligible. Does Medicare cover Zepbound covers both routes. Neither savings card can be used with Medicare or other government coverage.

How do the side effects compare?

Both labels carry the same boxed warning about the risk of thyroid C-cell tumors, and both report mainly gastrointestinal (stomach and bowel) reactions. The tables come from different trial programs in different patients, so the rates below describe each brand in its own trials. They aren’t a ranking, even with the molecule in common.

Mounjaro. In the label’s pool of two placebo-controlled trials in adults with type 2 diabetes, with a mean exposure of 36.6 weeks, nausea was reported by 12, 15 and 18 percent of patients on 5 mg, 10 mg and 15 mg, against 4 percent on placebo. Diarrhea was reported by 12, 13 and 17 percent, against 9 percent. The label says 3.0%, 5.4% and 6.6% of patients on the three doses stopped treatment because of gastrointestinal reactions, versus 0.4% on placebo.

Zepbound. In the label’s pool of two weight-reduction trials in adults with obesity or overweight, treated for up to 72 weeks, nausea was reported by 25, 29 and 28 percent of patients on 5 mg, 10 mg and 15 mg, against 8 percent on placebo. Diarrhea was reported by 19, 21 and 23 percent, against 8 percent. Across both trials, 4.8%, 6.3% and 6.7% of patients on the three doses permanently stopped treatment because of adverse reactions, compared with 3.4% on placebo.

The Zepbound trials ran longer and enrolled people with obesity or overweight, with or without diabetes, which is enough to explain why the tables don’t match. One point the labels share: low blood sugar is a particular concern with insulin or a sulfonylurea (a type of diabetes medicine). In the Zepbound trial in people with type 2 diabetes, hypoglycemia (low blood sugar) occurred in 10.3% of those also taking a sulfonylurea and 2.1% of those who weren’t. Each label’s full table appears on this page.

Switching between Mounjaro and Zepbound

People usually change brand because coverage or diagnosis changes: a plan covers one and not the other, or a prescription for weight management replaces one for diabetes.

The labels don’t describe the move. Each gives only its own starting dose, 2.5 mg once weekly, and no instruction for coming from another GLP-1 medicine. The strengths match, but no label says that a person on a given Mounjaro strength continues at that strength of Zepbound, and we won’t say it either. Your prescriber decides the starting point and writes a new prescription. You should be trained again if the form changes, for example from a single-dose pen to a vial.

Our page on switching from Mounjaro to Zepbound sets out what both labels say and compares the cost before and after. The switching planner does the same for other pairs.

Frequently asked questions

Mounjaro vs Zepbound: are they the same thing?

They're two Eli Lilly brands that both contain tirzepatide, in the same strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), injected once weekly. But they aren't one product with two names. Each has its own FDA label and its own approved uses. Mounjaro's are in type 2 diabetes. Zepbound's are weight reduction and moderate to severe obstructive sleep apnea in adults with obesity.

Is Zepbound cheaper than Mounjaro?

On self-pay, yes at every strength in our records. Mounjaro's LillyDirect price is $499 a month for the single-dose pen at any strength. Zepbound vials and KwikPen cost $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above when you refill within 45 days. With covered commercial insurance, both savings cards go as low as $25.

Can I use Mounjaro for weight loss?

Weight reduction isn't among Mounjaro's approved uses. Its label covers blood sugar control in adults and children 10 and older with type 2 diabetes, and cardiovascular risk reduction in adults with type 2 diabetes at high risk. The tirzepatide brand labeled for weight reduction is Zepbound. The Mounjaro savings card also requires a prescription consistent with the label.

Can I take Mounjaro and Zepbound together?

No. The Zepbound label states that it contains tirzepatide and that coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended. Mounjaro is a tirzepatide-containing product. You'd be prescribed one brand or the other.

Can I switch from Mounjaro to Zepbound at the same dose?

Neither label says. The Zepbound and Mounjaro labels give no instructions for switching from another GLP-1 medicine. Each gives only its own starting dose of 2.5 mg once weekly. Both brands come in matching strengths, but your prescriber decides whether you continue at your current strength or start lower, and it needs a new prescription.

Does Medicare cover Mounjaro or Zepbound?

Mounjaro for type 2 diabetes goes through your Part D plan, since CMS lists type 2 diabetes as an indication eligible for Part D coverage. Part D can cover Zepbound for obstructive sleep apnea. For weight management, the Medicare GLP-1 Bridge covers the Zepbound KwikPen only, at a $50 copay. Mounjaro isn't a Bridge product.

Sources (27)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  2. 2.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND once weekly at any time of day, with or without meals.”
  3. 3.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Administer MOUNJARO once weekly, any time of day, with or without meals.”
  4. 4.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”
  5. 5.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.”
  6. 6.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm. Rotate injection sites with each dose.”
  7. 7.
    FDA label (DailyMed): Zepbound prescribing information, section 2.2
    “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
  8. 8.
    FDA label (DailyMed): Zepbound prescribing information, section 2.1
    “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
  9. 9.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
  10. 10.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
  11. 11.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.4
    “The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
  12. 12.
    FDA label (DailyMed): Zepbound prescribing information, section 8.4
    “The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”
  13. 13.
    FDA label (DailyMed): Zepbound prescribing information, section 5.7
    “In this trial, patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%).”
  14. 14.
    FDA label (DailyMed): Mounjaro prescribing information, section 7.1
    “When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”
  15. 15.
    FDA label (DailyMed): Zepbound prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized (see Clinical Considerations).”
  16. 16.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.1
    “MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  17. 17.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  18. 18.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.